132 related articles for article (PubMed ID: 35394853)
1. Recurrent Anterior Non-necrotizing Scleritis as an Adverse Event of ChAdOx1 nCoV-19 (Vaxzevria) Vaccine.
Hernanz I; Arconada C; López Corral A; Sánchez-Pernaute O; Carreño E
Ocul Immunol Inflamm; 2022 Jul; 30(5):1247-1249. PubMed ID: 35394853
[TBL] [Abstract][Full Text] [Related]
2. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.
Kim SH; Lee SY; Kim GY; Oh JS; Kim J; Chun KJ; Ju MH; Lee CH; Song YJ; Na JY
J Korean Med Sci; 2022 Apr; 37(13):e104. PubMed ID: 35380028
[TBL] [Abstract][Full Text] [Related]
3. Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series.
Pillar S; Weinberg T; Amer R
Int Ophthalmol; 2023 May; 43(5):1677-1686. PubMed ID: 36316618
[TBL] [Abstract][Full Text] [Related]
4. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
5. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
[TBL] [Abstract][Full Text] [Related]
6. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex encephalitis following ChAdOx1 nCoV-19 vaccination: a case report and review of the literature.
Moslemi M; Ardalan M; Haramshahi M; Mirzaei H; Sani SK; Dastgir R; Dastgir N
BMC Infect Dis; 2022 Mar; 22(1):217. PubMed ID: 35241013
[TBL] [Abstract][Full Text] [Related]
8. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
[TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus retinitis following ChAdOx1 nCoV- 19 (Covishield) vaccination for SARS CoV 2: A case report.
Singh J; More A; Shetty SB; Chaskar P; Sen A
Ocul Immunol Inflamm; 2022 Jul; 30(5):1282-1285. PubMed ID: 35587646
[TBL] [Abstract][Full Text] [Related]
10. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
[TBL] [Abstract][Full Text] [Related]
11. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
12. Sequential provocation of Ekbom's syndrome and acute mania following AstraZeneca COVID-19 vaccination.
Chang FY; Chen PA; Siao WH; Chen YC
Asian J Psychiatr; 2023 May; 83():103569. PubMed ID: 37012199
[TBL] [Abstract][Full Text] [Related]
13. Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination.
Spataro R; Fisco G; La Bella V
BMJ Case Rep; 2022 Feb; 15(2):. PubMed ID: 35110289
[TBL] [Abstract][Full Text] [Related]
14. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
[TBL] [Abstract][Full Text] [Related]
15. Generalized Edema and Pseudothrombocytopenia After ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Report.
Bokel J; Mendes-de-Almeida DP; Martins-Gonçalves R; Palhinha L; Vizzoni AG; Correa DF; Brandão LGP; Bozza PT; Grinsztejn B
Front Public Health; 2022; 10():907652. PubMed ID: 35692333
[TBL] [Abstract][Full Text] [Related]
16. Bilateral Immune-Mediated Keratolysis After Immunization With SARS-CoV-2 Recombinant Viral Vector Vaccine.
Khan TA; Sidhu N; Khan L; Sen S; Hussain N; Tandon R; Gupta N
Cornea; 2021 Dec; 40(12):1629-1632. PubMed ID: 34483273
[TBL] [Abstract][Full Text] [Related]
17. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.
Nasuelli NA; De Marchi F; Cecchin M; De Paoli I; Onorato S; Pettinaroli R; Savoini G; Godi L
Neurol Sci; 2021 Nov; 42(11):4747-4749. PubMed ID: 34272622
[TBL] [Abstract][Full Text] [Related]
18. Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single center.
Jeong YJ; Kim YJ; Kim SH; Yoo J; Lee J; Lee S; Il Kim S
J Infect Public Health; 2022 Mar; 15(3):360-364. PubMed ID: 35193817
[TBL] [Abstract][Full Text] [Related]
19. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant).
Sandhu S; Bhatnagar A; Kumar H; Dixit PK; Paliwal G; Suhag DK; Patil C; Mitra D
Dermatol Ther; 2021 Nov; 34(6):e15141. PubMed ID: 34546608
[TBL] [Abstract][Full Text] [Related]
20. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.
Zamai L; Rocchi MBL
Br J Pharmacol; 2022 Jan; 179(2):218-226. PubMed ID: 34331459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
